secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARVINAS, INC. (ARVN)
CIK:        0001655759
Form:       8-K
Filed at:   2025-10-20T23:59:59+00:00
Accession:  0001628280-25-045445
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arvinas reports positive PRO data from Phase 3 VERITAC-2 for vepdegestrant in ESR1-mutated breast cancer
--------------------------------------------------------------------------------

- Vepdegestrant showed reduced risk of deterioration vs fulvestrant in overall health status, pain severity, and functioning domains; statistically significant.
- PRO data presented at ESMO 2025 support vepdegestrant as potential best-in-class therapy for ESR1-mutated ER+/HER2- metastatic breast cancer.
- Also presented TACTIVE-N Phase 2 results: neoadjuvant vepdegestrant demonstrated biological and clinical activity in localized breast cancer.
- Vepdegestrant is a PROTAC ER degrader developed with Pfizer; previously reported statistically significant PFS improvement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1655759/000162828025045445/0001628280-25-045445-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1655759/000162828025045445/arvn-20251020.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-045445

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer